Skip to main content

Drug repurposing in pancreatic ductal adenocarcinoma

Project description

New roles of nischarin receptor agonists in the treatment of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer with a five-year survival rate of less than 5 %. The goal of the EU-funded REPANCAN project is to decrease the high cost and long development time of new drugs using the drug repurposing concept for a class of nischarin receptor agonists. Previously, the nischarin receptor demonstrated tumour suppressor activity in breast cancer, and its agonists might target the PDAC-associated cell invasiveness, survival, metabolism and tumour microenvironment. The project will combine bioinformatics, molecular and cellular research approaches aiming to establish a ground for repurposing low-cost drugs with proven safety to treat one of the most lethal and understudied types of cancer.

Coordinator

INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE
Net EU contribution
€ 140 021,76
Address
14 Pasterova St.
11000 Belgrade
Serbia

See on map

Region
Србија - север Београдски регион Београдска област
Activity type
Other
Non-EU contribution
€ 0,00